[
  {
    "ts": null,
    "headline": "Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea速",
    "summary": "According to the settlement agreement, the proposed biosimilar to Eylea速 (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances REYKJAVIK, Iceland and TEL AVIV, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Ind",
    "url": "https://finnhub.io/api/news?id=3035cd56d70caa262d2a126d8ffc01a6d879bff44221ed6d15485f2b377fdace",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766133600,
      "headline": "Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea速",
      "id": 137831708,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "According to the settlement agreement, the proposed biosimilar to Eylea速 (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances REYKJAVIK, Iceland and TEL AVIV, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Ind",
      "url": "https://finnhub.io/api/news?id=3035cd56d70caa262d2a126d8ffc01a6d879bff44221ed6d15485f2b377fdace"
    }
  }
]